Results 271 to 280 of about 3,900,516 (357)
Use of Tranexamic Acid in Head and Neck Free Flap Reconstruction. [PDF]
Bengur FB+13 more
europepmc +1 more source
Porous polyethylene in reconstructive head and neck surgery [PDF]
Berghaus, Alexander
core +1 more source
Selective lesioning of SuM glutamatergic neurons promoted the induction of and delayed emergence from sevoflurane anesthesia and increased sevoflurane sensitivity. Optogenetic stimulation of SuM glutamatergic neurons or the SuM‐MS projection promoted behavioral arousal and cortical activation under steady‐state sevoflurane anesthesia and reduced the ...
Jiayan Li+8 more
wiley +1 more source
Nanotechnology in the perioperative treatment of head and neck cancer: application and outlook. [PDF]
Zhou JJ+4 more
europepmc +1 more source
Bilirubin Targeting WNK1 to Alleviate NLRP3‐Mediated Neuroinflammation
At physiological concentrations, bilirubin binds to the kinase domain of WNK1, thereby augmenting its activity and facilitating the phosphorylation of downstream SPAK/OSR1. This phosphorylation inhibits KCC2 activity, leading to elevate intracellular chloride levels in neurons.
Linfei Mao+14 more
wiley +1 more source
Magnetic resonance permeability for the evaluation of head and neck tumors: Parotid and beyond. [PDF]
Nagano SYM, Chojniak R, Porto GCLM.
europepmc +1 more source
A type of polydopamine (PDA) nanogel decorated adhesive and responsive hierarchical microcarriers for ALA delivery and deafness prevention. PDA@microcarriers can protect the encapsulated drugs from external disturbances and prolong their retention time in the inner ear.
Hong Chen+8 more
wiley +1 more source
D‐galactose (D‐gal) induced inner ear hair cell senescence by inhibiting TFEB transcription. RONIN/HCF1 promotes TFEB transcription to prevent cochlear HCs from D‐gal‐induced senescence through autophagy activation. Abstract Age‐related hearing loss is characterized by senescent inner ear hair cells (HCs) and reduced autophagy.
Yongjie Wei+18 more
wiley +1 more source
Identifying factors for pembrolizumab eligibility in head and neck cancer. [PDF]
Miyamaru S+3 more
europepmc +1 more source